Empagliflozin And Canagliflozin Attenuate Inflammatory Cytokines Interferon-Gamma, Tumor Necrosis Factor-Alpha, Interleukin-6: Possible Mechanism Of Decreasing Cardiovascular Risk In Diabetes Mellitus

SGLT2 inhibitor canagliflozin decreases Hgb A1c better than empagliflozin; but empagliflozin decreases the cardiovascular risk in diabetics more than canagliflozin. Inflammatory cytokines Interferon-λ (IFN-λ), Tumor Necrosis Factor-α (TNF-α), u0026 Interleukin-6 (IL-6) are implicated as